Oral Ibrutinib (single agent)
|
|
|
- Kerry Ryan
- 5 years ago
- Views:
Transcription
1 Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM IBRUTINIB Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other identifier) Male Female Special requirements (e.g. other language/other communication method) Treatment for Relapsed or Refractory Mantle Cell Lymphoma Oral Ibrutinib (single agent) Responsible health professional Job title Name of proposed procedure or course of treatment (include brief explanation if medical term not clear) Oral ibrutinib capsules taken once a day continuously Treatment continued at the discretion of the treating doctor Location of administration: Outpatient Day unit Inpatient Other
2 Patient identifier/label: Page 2 of 6 Statement of health professional (to be filled in by health professional with appropriate knowledge of proposed procedure, as specified in consent policy) I have explained the procedure to the patient. In particular, I have explained: The intended benefits Improved survival Control of symptoms Disease control the aim is not to cure but to control disease. The aim is to improve both quality of life and survival Significant, unavoidable or frequently occurring risks: Common side-effects include diarrhoea, tiredness, feeling sick (nausea) and being sick (vomiting), sore mouth and ulcers, skin rash, muscle or joint pain, headaches, blurred vision or dizziness. Other side-effects include: anaemia (low number of red blood cells), and reduction in the number of platelets which may cause bruising/bleeding. It is vital that you contact your doctor or the hospital if you experience prolonged bleeding or regular nose bleeds, bleeding of gums and red/dark brown colour of urine. You may be asked to stop treatment if you need surgery Ibrutinib may cause heart problems such as changes in your heart rhythm or breathlessness. You may feel dizzy, faint, or have a fast, pounding or uneven heartbeat/irregular heart rhythm. Ibrutinib may also cause fluid retention (swollen hands, feet or ankles) Less common, but a potentially life threatening side-effect is reduced resistance to infection. It is vital that you contact your doctor or the hospital or if outside of normal working hours the on-call hospital doctor straight away if: your temperature goes above 38ºC (100.4ºF) you suddenly feel unwell (even with a normal temperature). Your doctor or nurse will give you the phone numbers to call should these symptoms occur. These symptoms indicate that you have an infection. It is an emergency and it is very important that you contact the hospital / your doctor. Increased risk of tumour lysis syndrome in the presence of high tumour burden (high number of cancer cells present in the body). This means symptoms caused by breakdown of cancer cells initiated by the treatment. High risk patients will be prescribed preventative supplementary medicines. Cases of leukostasis have been reported in patients treated with ibrutinib. A high number of circulating lymphocytes may confer increased risk.
3 Patient identifier/label: Page 3 of 6 Cancer can increase your risk of developing a blood clot (thrombosis), and having anti-cancer treatment may increase this risk further. A blood clot may cause pain, redness and swelling in a leg, or breathlessness and chest pain - you must tell your doctor straight away if you have any of these symptoms. Some anti cancer drugs can damage women s ovaries and men s sperm, with risk of infertility and early menopause in women. I have warned the patient about the likelihood of: early menopause in women infertility (in men and in women) Some anti cancer drugs may damage the development of a baby in the womb (foetus), leading to the many risks associated with an abnormal pregnancy. Therefore, I have discussed the importance of protected sex and the use of double barrier method of contraception. This is an issue for both men and women. The patient has been advised not to become pregnant / not to get a partner pregnant during the period of treatment, and for 3 months after finishing the treatment. Any other risks:... What the treatment is likely to involve (including inpatient / outpatient treatment, timing of the treatment, follow-up appointments etc) and location. I have also discussed the benefits and risks of any available alternative treatments (including no treatment) and any particular concerns of this patient. The following leaflet/tape has been provided: Patient information leaflet / treatment plan for ibrutinib 24 hour chemotherapy service contact details.. Signed:. Name (PRINT). Date.... Job title... Contact details (if patient wishes to discuss options later)... Statement of interpreter (where appropriate) Language Line ref:
4 Patient identifier/label: Page 4 of 6 I have interpreted the information above to the patient to the best of my ability and in a way in which I believe s/he can understand. Signed.. Date... Name (PRINT).. Copy accepted by patient: yes/no (please ring)
5 Patient identifier/label: Page 5 of 6 Statement of patient Please read this form carefully. Page 2 describes the benefits and risks of the proposed treatment, you will be offered a copy of this form. If you have any further questions, do ask we are here to help you. You have the right to change your mind at any time, including after you have signed this form. I agree to the procedure and course of treatment described on this form. I understand that you cannot give me a guarantee that a particular person will perform the procedure. The person will, however, have appropriate training and experience. I understand that any procedure in addition to those described on this form will only be carried out if it is necessary to save my life or to prevent serious harm to my health. I have been told about additional procedures which may become necessary during my treatment. I have listed below any procedures which I do not wish to be carried out without further discussion. Patient s signature.. Date.. Name (PRINT) A witness should sign below if the patient is unable to sign but has indicated his or her consent. Young people/children may also like a parent to sign here (see notes). Signature Date... Name (PRINT). Confirmation of consent (to be completed by a health professional when the patient is admitted for the procedure, if the patient has signed the form in advance) On behalf of the team treating the patient, I have confirmed with the patient that s/he has no further questions and wishes the procedure to go ahead. Signed:. Name (PRINT). Date.... Job title... Important notes: (tick if applicable) See also advance decision (eg Jehovah s Witness form) Patient has withdrawn consent (ask patient to sign /date here)....
6 Patient identifier/label: Page 6 of 6 Guidance to health professionals (to be read in conjunction with consent policy) What a consent form is for This form documents the patient s agreement to go ahead with the investigation or treatment you have proposed. It is not a legal waiver if patients, for example, do not receive enough information on which to base their decision, then the consent may not be valid, even though the form has been signed. Patients are also entitled to change their mind after signing the form, if they retain capacity to do so. The form should act as an aide-memoire to health professionals and patients, by providing a check-list of the kind of information patients should be offered, and by enabling the patient to have a written record of the main points discussed. In no way, however, should the written information provided for the patient be regarded as a substitute for face-to-face discussions with the patient. The law on consent See the Department of Health s Reference guide to consent for examination or treatment for a comprehensive summary of the law on consent (also available at Who can give consent Everyone aged 16 or more is presumed to have the capacity to give consent for themselves, unless the opposite is demonstrated. If a child under the age of 16 has sufficient understanding and intelligence to enable him or her to understand fully what is proposed, then he or she will have the capacity to give consent for himself or herself. Young people aged 16 and 17, and legally competent younger children, may therefore sign this form for themselves, but may like a parent to countersign as well. If the child is not able to give consent for himself or herself, some-one with parental responsibility may do so on their behalf and a separate form is available for this purpose. Even where a child is able to give consent for himself or herself, you should always involve those with parental responsibility in the child s care, unless the child specifically asks you not to do so. If a patient has the mental capacity to give consent but is physically unable to sign a form, you should complete this form as usual, and ask an independent witness to confirm that the patient has given consent orally or non-verbally. When NOT to use this form If the patient is 18 or over and lacks the capacity to give consent, you should use form 4 (form for adults who lack the capacity to consent to investigation or treatment) instead of this form. A patient lacks capacity if they have an impairment of the mind or brain or disturbance affecting the way their mind or brain works and they cannot: understand information about the decision to be made retain that information in their mind use or weigh that information as part of the decision-making process, or communicate their decision (by talking, using sign language or any other means). You should always take all reasonable steps (for example involving more specialist colleagues) to support a patient in making their own decision, before concluding that they are unable to do so. Relatives cannot be asked to sign a form on behalf of an adult who lacks capacity to consent for themselves, unless they have been given the authority to so under a Lasting Power of Attorney or as a court appointed deputy. Information Information about what the treatment will involve, its benefits and risks (including side-effects and complications) and the alternatives to the particular procedure proposed, is crucial for patients when making up their minds. The courts have stated that patients should be told about significant risks which would affect the judgement of a reasonable patient. Significant has not been legally defined, but the GMC requires doctors to tell patients about serious or frequently occurring risks. In addition if patients make clear they have particular concerns about certain kinds of risk, you should make sure they are informed about these risks, even if they are very small or rare. You should always answer questions honestly. Sometimes, patients may make it clear that they do not want to have any information about the options, but want you to decide on their behalf. In such circumstances, you should do your best to ensure that the patient receives at least very basic information about what is proposed. Where information is refused, you should document this on page 2 of the form or in the patient s notes. References: 1- South East London Cancer Network, Agreed lists of Chemotherapy Regimens 2- Macmillan Cancer Support, Cancer Information 3- Royal Marsden NHS Foundation Trust, Consent Forms
Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM IMATINIB. Patient s first names.
Patient identifier/label: Page 1 of 5 Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS number
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE CONTINUOUS INFUSION
Patient identifier/label: Page 1 of 6 CYTARABINE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PEGYLATED LIPOSOMAL DOXORUBICIN (CAELYX)
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PEGYLATED LIPOSOMAL DOXORUBICIN (CAELYX) Patient s surname/family name Patient s first names Date of birth Hospital
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DOCETAXEL + PREDNISOLONE. Patient s first names
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DOCETAXEL + PREDNISOLONE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM VISMODEGIB. Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM VISMODEGIB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PAZOPANIB. Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PAZOPANIB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas
Patient identifier/label: Page 1 of 6. Patient s first names. Date of birth
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ENZALUTAMIDE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FMD. Patient s first names.
Patient identifier/label: Page 1 of 6 Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS number
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 + RITUXIMAB
Patient identifier/label: Page 1 of 6 FORM CHOP 21 + RITUXIMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM TRASTUZUMAB (HERCEPTIN) Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM TRASTUZUMAB (HERCEPTIN) Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number
PATIENT AGREEMENT TO SYSTEMIC THERAPY: GENERIC CONSENT FORM. Patient s first names. Date of birth. Job title
Patient identifier/label: Page 1 of 5 GENERIC CONSENT FORM Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other identifier) Male Female Special requirements
PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM WEEKLY RITUXIMAB. Patient s first names. Date of birth
Page 1 of 5 FORM WEEKLY RITUXIMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS number
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine-Cisplatin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine-Doxorubicin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Lomustine PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Vinorelbine (oral) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cetuximab (+/- platinum-based chemotherapy) HOSPITAL NAME/STAMP: PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cetuximab (+/- Chemotherapy) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DENOSUMAB. Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DENOSUMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Lenvatinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cabozantinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
Patient agreement to investigation, treatment or procedure
Appendix A: Consent Form 1 Consent form 1 Patient agreement to investigation, treatment or procedure Patient details (or pre-printed label) Patient s surname/family name... Patient s first names.. Date
CONSENT FORM UROLOGICAL SURGERY
CONSENT FORM for UROLOGICAL SURGERY (Designed in compliance with consent form 1) PATIENT AGREEMENT TO INVESTIGATION OR TREATMENT Patient Details or pre-printed label Patient s NHS Number or Hospital number
Cobimetinib (Cotellic ) ( koe-bi-me-ti-nib )
Cobimetinib (Cotellic ) ( koe-bi-me-ti-nib ) How drug is given: by mouth Purpose: to stop the growth of melanoma cancer cells How to take this drug 1. This drug can be taken with or without food. 2. Swallow
Sentinel node biopsy. Patient Information to be retained by patient
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label Sentinel Node Biopsy What is a sentinel node biopsy? The lymphatic drainage from your
Top copy accepted by patient: yes/no (please ring)
Consent Form 3 Patient / Parental agreement to investigation or treatment Procedures where consciousness not impaired Name of proposed procedure or course of treatment Hospital NHS Surname no: no: OUTPATIENT
New Patient Registration Form NJR_NP_F100
New Patient Registration Form NJR_NP_F100 Patient Last Name First Name Middle Name Maiden Name Address (Street or Box) City State Zip Code Home Phone Number Cell Phone Number Work Phone Number E-Mail Patient
Treatment of non-muscle invasive bladder cancer with BCG and EMDA MMC
Treatment of non-muscle invasive bladder cancer with BCG and EMDA MMC This information sheet has been given to you to explain the combined use of BCG and EMDA MMC to treat your non-muscle invasive bladder
Retina Center of Oklahoma Demographic Information Sam S. Dahr,MD
Retina Center of Oklahoma Demographic Information Sam S. Dahr,MD PATIENT LAST NAME: FIRST NAME: MI: MAILING ADDRESS: CITY: STATE: ZIP CODE: HOME PHONE: WORK PHONE: CELL PHONE: MARITAL STATUS: DATE OF BIRTH:
Care of Your Peripherally Inserted Central Catheter
Care of Your Peripherally Inserted Central Catheter A guide for patients and their carers Acute Oncology Patient Information Leaflet Contents Information for patients: What is a PICC? How is it put in?
Generator or box changes for your implantable device
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a generator? The generator (sometimes called the box ) is the battery that
WITHOUT YOUR WRITTEN CONSENT, WE CAN NOT SPEAK TO ANYONE REGARDING YOUR MEDICAL CARE due to privacy laws. You have the right to list anyone you
PATIENT REGISTRATION FORM PLEASE PRINT : Referring Physician: Primary Care: Patient s Name: Last First: M.I. Address: City: State: Zip: Home Phone: Cell: Work: Email: Preferred Contact Method Race: Ethnicity:
SMG OB/GYN Lake Lansing St. Johns Returning Patient Questionnaire (Please print clearly and Fill out Entirely)
SMG OB/GYN Lake Lansing St. Johns Returning Patient Questionnaire (Please print clearly and Fill out Entirely) Name: Former/ Maiden Name: Date of Birth: Age: Today s Date: *Language: Race: Ethnicity: *Do
Patient copy. Periurethral bulking agent for stress urinary incontinence. Patient Information to be retained by patient
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label Who is this leaflet for? This leaflet provides information about having an injection
Preventing hospital-acquired blood clots
Preventing hospital-acquired blood clots Haematology Department Patient information leaflet This leaflet explains more about blood clots, which can form after illness and surgery. What are hospital-acquired
Laparoscopy. Women's Health Unit. Patient Information Leaflet
Laparoscopy Women's Health Unit Patient Information Leaflet February 2017 WHAT IS A LAPAROSCOPY? Laparoscopy is direct visual examination of the inside of the abdomen, using a viewing device called a laparoscope.
Abiraterone Acetate (Zytiga )
Abiraterone Acetate (Zytiga ) ( a-bir-a-ter-one AS-e-tate ) How drug is given: By mouth Purpose: To stop the growth of cancer cells in prostate cancer How to take this drug 1. Take this medication on an
Trans Urethral Resection of Bladder Tumour (TURBT) (Day Case)
Trans Urethral Resection of Bladder Tumour (TURBT) (Day Case) Department of Urology Information for patients i What is a Trans Urethral Resection of Bladder Tumour (TURBT)? Your recent cystoscopy has shown
Last Name: First Name: Advance Directive including Power of Attorney for Health Care
Patient Medical Record Number: Or Label Advance Directive including Power of Attorney for Health Care Overview This legal document meets the requirements for Wisconsin.* It lets you Name another person
Coordinating Access to Obtain ZOLINZA
ACT Now: 1-866-363-6379 Coordinating Access to Obtain ZOLINZA Reimbursement Support Services Patient Assistance BEFORE YOU LEAVE, please have your physician s office fax your prescription for ZOLINZA and
Etoposide (VePesid ) ( e-toe-poe-side )
Etoposide (VePesid ) ( e-toe-poe-side ) How drug is given: by mouth Purpose: to stop the growth of cancer cells in ovarian cancer, small cell lung cancer, Hodgkin disease, and other cancers How to take
Deep Vein Thrombosis (DVT) - Blood Clots
Patient information Deep Vein Thrombosis (DVT) - Blood Clots i Important information for all patients. Golden Jubilee National Hospital Agamemnon Street Clydebank, G81 4DY (: 0141 951 5000 www.nhsgoldenjubilee.co.uk
Children s Ward Parent/Carer Information Leaflet
Operation to remove tonsils Children s Ward Parent/Carer Information Leaflet Introduction Your child s consultant has suggested that your child has an operation to remove their tonsils. This leaflet explains
University College London Hospitals (UCLH) Preventing venous thromboembolism (VTE)
University College London Hospitals (UCLH) Preventing venous thromboembolism (VTE) Information for adult inpatients and for patients due to be admitted If you need a large print, audio, braille, easy read
WELCOME TO THE UPMC LIVER CANCER CENTER PLEASE FILL OUT AND BRING WITH YOU TO YOUR APPOINTMENT
WELCOME TO THE UPMC LIVER CANCER CENTER PLEASE FILL OUT AND BRING WITH YOU TO YOUR APPOINTMENT You are scheduled to have an appointment at the UPMC Liver Cancer Center which is located in the UPMC Montefiore
Having a blue light cystoscopy
Having a blue light cystoscopy The aim of this information sheet is to help answer some of the questions you may have about having a blue light cystoscopy. It explains the benefits, risks and alternatives
Hickman line insertion and caring for your line
Hickman line insertion and caring for your line Information for patients This booklet explains how a Hickman line is put in, the benefits, the risks and the alternatives, as well as how to care for your
Bowel Screening Wales Information booklet for care homes and associated health professionals. Available in other formats on request. October.14.v.2.
Bowel Screening Wales Information booklet for care homes and associated health professionals Available in other formats on request October.14.v.2.0 Contents Section 1 Page 3 Who are Bowel Screening Wales
Last Name: First Name: Advance Directive. including Power of Attorney for Health Care
Overview Patient Medical Record Number: Or Label Advance Directive including Power of Attorney for Health Care This legal document meets the requirements for Wisconsin.* It lets you Name another person
Covert Administration of Medicines Policy and Procedure
1 Final Draft 1. Policy Covert Administration of Medicines Policy and Procedure 1.1 Why? The Nursing and Midwifery Council has recognised there will be instances where it is appropriate to administer medication
Wirral Community NHS Trust Consent Form 4
Wirral Community NHS Trust Consent Form 4 Form for adults who are unable to Consent to investigation or treatment Patient details (or pre-printed label) Patient's surname/family name Patients first names
Cyclophosphamide INFUSION Infusion 4 Plus
Cyclophosphamide Infusion Day DEPARTMENT OF RHEUMATOLOGY DAY CASE ADMISSION RECORD PATIENT DAY CASE BOOKING REQUEST To be completed by Consultant, Registrar requesting day case Admission Hospital No. Forename
Information for patients with gynaecological cancer. Departments of gynaecology, oncology and gynaecological oncology
Information for patients with gynaecological cancer Departments of gynaecology, oncology and gynaecological oncology This booklet gives further information about cancers of the female reproductive system
DOUGLAS JAY SPRUNG MD, FACG, FACP The Gastroenterology Group
DOUGLAS JAY SPRUNG MD, FACG, FACP The Gastroenterology Group Date: NAME: AGE: DOB: Why are you here to see the doctor today? REFERRED BY: INSURANCE HEALTH GRADES INTERNET FRIENDS/RELATIVES PCP OTHER: Medications
Last Name First Middle. Mailing Address. City State Zip Phone. Date of Birth Age Soc. Sec# Cell. Employer Work Phone
Last Name First Middle Mailing Address City State Zip Phone Date of Birth Age Soc. Sec# Cell Employer Work Phone Email Address Emergency contact Phone # Relation: Name of Primary Insurance Policy # -----
Instruction Sheet for Completing Health Care Power of Attorney/Living Will (Please discard instruction sheet after completion of document)
Instruction Sheet for Completing Health Care Power of Attorney/Living Will (Please discard instruction sheet after completion of document) Overview The attached Power of Attorney for Health Care form is
Health Care Directive
MINNESOTA PATIENT EDUCATION Health Care Directive Making Your Health Care Choices Known My Health Care Directive My health care directive was created to guide my health care agent and family, friends or
Insertion of a ventriculo-peritoneal or ventriculo-atrial shunt
Department of Neurosurgery Insertion of a ventriculo-peritoneal or ventriculo-atrial shunt Information for patients Shunt surgery This leaflet explains what to expect when you are in hospital and during
Cooley Chiropractic. Date of Birth. Married Single Spouse Name. Street City State Zip. . Name. Occupation. Current Symptoms. When Symptoms began
Please Print Clearly Date NAME: Date of Birth Male Female Married Single Spouse Name Address: Street City State Zip Home Phone Cell Phone E-mail In Case of Emergency please contact: Name Phone Relationship
~ Rhode Island ~ Durable Power of Attorney For Health Care Christian Version
~ Rhode Island ~ Durable Power of Attorney For Health Care Christian Version NOTICE TO PERSON MAKING THIS DOCUMENT You have the right to make decisions about your health care. No health care may be given
COLON & RECTAL SURGERY, INC.
COLON & RECTAL SURGERY, INC. Please complete attached paperwork and bring to your appointment with your insurance card, co-pay and photo ID. If a referral is required, please be sure to contact your insurance
Are you at risk of blood clots?
Are you at risk of blood clots? DVT (deep vein thrombosis) & PE (pulmonary embolism) Information for patients in hospital or going home from hospital Are you at risk of blood clots? (DVT & PE) This leaflet
~ Arizona. Power of Attorney For Health Care Christian Version NOTICE TO PERSON MAKING THIS DOCUMENT
~ Arizona ~ Power of Attorney For Health Care Christian Version NOTICE TO PERSON MAKING THIS DOCUMENT You have the right to make decisions about your health care. No health care may be given to you over
Advance Directive. including Power of Attorney for Health Care
Advance Directive including Power of Attorney for Health Care Overview This is a legal document, developed to meet the legal requirements for Wisconsin. This document provides a way for a person to create
Abbvie 3D for the treatment of Hepatitis C Genotype 1
Abbvie 3D for the treatment of Hepatitis C Genotype 1 Department of Hepatology Digestive Diseases Centre Patient Information This leaflet is designed to give you important information about your new medicine.
Welcome to our Chiropractic Office! P l e a s e P r i n t C l e a r l y a n d f i l l I n c o m p l e t e l y.
Welcome to our Chiropractic Office! P l e a s e P r i n t C l e a r l y a n d f i l l I n c o m p l e t e l y. Print Name Email Street Address Phone City State Zip Date of Birth Please Check Sex: Male
Having a staging laparoscopy
Information for patients Having a staging laparoscopy Turnberg Building Upper GI General Surgery 0161 206 5062 Page 1 of 5 This booklet has four aims: l To help you and your family become better informed
~ Minnesota. Durable Power of Attorney for Health Care Christian Version NOTICE TO PERSON MAKING THIS DOCUMENT
~ Minnesota ~ Durable Power of Attorney for Health Care Christian Version NOTICE TO PERSON MAKING THIS DOCUMENT YOU HAVE THE RIGHT TO MAKE DECISIONS ABOUT YOUR HEALTH CARE. NO HEALTH CARE MAY BE GIVEN
~ Wisconsin. Power of Attorney For Health Care Christian Version NOTICE TO PERSON MAKING THIS DOCUMENT
~ ~ Power of Attorney For Health Care Christian Version NOTICE TO PERSON MAKING THIS DOCUMENT You have the right to make decisions about your health care. No health care may be given to you over your objection,
INFORMATION FOR PATIENTS
The British Association of Urological Surgeons 35-43 Lincoln s Inn Fields London WC2A 3PE Phone: Fax: Website: E- mail: +44 (0)20 7869 6950 +44 (0)20 7404 5048 www.baus.org.uk admin@baus.org.uk INFORMATION
Methylprednisolone and Cyclophosphamide for lung fibrosis Information for patients
Methylprednisolone and Cyclophosphamide for lung fibrosis Information for patients This leaflet can be made available in other formats including large print, CD and Braille and in languages other than
Advance Health Care Planning: Making Your Wishes Known. MC rev0813
Advance Health Care Planning: Making Your Wishes Known MC2107-14rev0813 What s Inside Why Health Care Planning Is Important... 2 What You Can Do... 4 Work through the advance health care planning process...
Burton M. Sundin, M.D. / Reps B. Sundin, M.D. Date: Name (Last, First, MI): Address: Zip, City, State: Home#: Work#: Cell#: address:
Date: Name (Last, First, MI): Address: Zip, City, State: Home#: Work#: Cell#: Email address: Patient Status: 1-Married 2 Single 3-Separated 4-Divorced 5-Widowed 6-Other Birthdate: Sex: Social Security#:
Patient & Family Guide. Blood Transfusion. Aussi disponible en français : La transfusion sanguine (FF )
Patient & Family Guide 2017 Blood Transfusion Aussi disponible en français : La transfusion sanguine (FF85-1811) www.nshealth.ca Blood Transfusion You have been given this pamphlet because you or your
CHPCA appreciates and thanks our funding partner GlaxoSmithKline for their unrestricted funding support for Advance Care Planning in Canada.
CHPCA appreciates and thanks our funding partner GlaxoSmithKline for their unrestricted funding support for Advance Care Planning in Canada. For more information about advance care planning, please visit
Harvoni for the treatment of Hepatitis C
Harvoni for the treatment of Hepatitis C Department of Hepatology Digestive Diseases Centre Patient Information This leaflet is designed to give you important information about your new medicine. It is
Bellevue Neurology PATIENT DEMOGRAPHIC FORM
PATIENT DEMOGRAPHIC FORM Name Today s date / / Last First M.I. Mailing Address Age Number, Street, Apartment Number City State Zip Home Phone ( ) Work Phone ( ) Cell Phone ( ) Date of Birth / / SS # Marital
MRSA INFORMATION LEAFLET for patients and relatives. both in hospital and the community. MRSA is a type of
MRSA INFORMATION LEAFLET for patients and relatives WHAT DOES MRSA STAND FOR? Meticillin Resistant Staphylococcus aureus. WHAT IS MRSA? Staphylococcus aureus is a germ that is commonly found both in hospital
~ Idaho. Durable Power of Attorney for Health Care Christian Version NOTICE TO PERSON MAKING THIS DOCUMENT
~ Idaho ~ Durable Power of Attorney for Health Care Christian Version NOTICE TO PERSON MAKING THIS DOCUMENT You have the right to make decisions about your health care. No health care may be given to you
Blood clot prevention. A guide for patients and carers
Blood clot prevention A guide for patients and carers Contents Introduction 1 What is a venous thromboembolism (VTE)? 1 What is a deep vein thrombosis (also known as a DVT)? 1 What is a pulmonary embolism
The Newcastle upon Tyne Hospitals NHS Foundation Trust
The Newcastle upon Tyne Hospitals NHS Foundation Trust Advance Decision to Refuse Treatment Policy (Advanced Refusal of Treatment/ Previously known as Living Wills) Incorporating the Mental Capacity Act
Sentinel Node Biopsy for Breast Cancer
Sentinel Node Biopsy for Breast Cancer Breast Care Centre Information for Patients Name of Consultant: i... Date of surgery:... Key worker:... Direct line: 0116 250 2513 Monday - Friday 9 am - 4 pm (except
~ Colorado. Medical Durable Power of Attorney for Healthcare Decisions Christian Version NOTICE TO PERSON MAKING THIS DOCUMENT
~ Colorado ~ Medical Durable Power of Attorney for Healthcare Decisions Christian Version NOTICE TO PERSON MAKING THIS DOCUMENT You have the right to make decisions about your health care. No health care
~ Wisconsin. Power of Attorney For Health Care Christian Version NOTICE TO PERSON MAKING THIS DOCUMENT
~ Wisconsin ~ Power of Attorney For Health Care Christian Version NOTICE TO PERSON MAKING THIS DOCUMENT You have the right to make decisions about your health care. No health care may be given to you over
LIVING WILL AND ADVANCE DIRECTIVES. Exercise Your Right: Put Your Healthcare Decisions in Writing.
LIVING WILL AND ADVANCE DIRECTIVES Exercise Your Right: Put Your Healthcare Decisions in Writing. Maryland Advance Directive A Message from the Maryland Attorney General Adults can decide for themselves
LIVING WILL AND ADVANCE DIRECTIVES. Exercise Your Right: Put Your Healthcare Decisions in Writing
LIVING WILL AND ADVANCE DIRECTIVES Exercise Your Right: Put Your Healthcare Decisions in Writing Maryland Advance Directive A Message from the Maryland Attorney General Adults can decide for themselves
New Patient Paperwork
Your Vision Is Our Focus New Patient Paperwork Dear Patient, Please fill out all of the following pages, and bring them with you to your scheduled appointment time. If you have questions regarding your
NHS Continuing Health Care Consent Form
NHS Continuing Health Care Consent Form Surname/family name (of individual being assessed) First names Date of birth: NHS number (or other identifier)... Responsible professional 1 Name:...... Job title...
Enhanced Recovery Programme for total hip and knee replacement Orthopaedic Department Patient Information Leaflet
Enhanced Recovery Programme for total hip and knee replacement Orthopaedic Department Patient Information Leaflet What is the Enhanced Recovery Programme? This leaflet aims to give you information on what
Statement of Financial Responsibility
Statement of Financial Responsibility Patient Name: Date: Acct : BIR JV, LLP including; Out-Patient, In-Patient and, Home Health Rehab appreciates the confidence you have shown in choosing us to provide
Welcome to OPEN DOORS
Welcome to OPEN DOORS A support program for IPF patients taking OFEV (nintedanib) capsules For more information, call OPEN DOORS at 1-866-OPENDOOR (1-866-673-6366), or visit www.ofev.com IPF=idiopathic
PAYMENT IS REQUIRED AT THE TIME SERVICES ARE RENDERED. THANK YOU!
PATIENT INFORMATION FORM PATIENT DATA: - - PATIENT NAME (LAST, FIRST, MIDDLE) SOCIAL SECURITY # SEX ( ) - ( ) - ADDRESS HOME PHONE NUMBER MOBILE PHONE NUMBER CITY STATE ZIP CODE OCCUPATION / / DATE OF
~ Massachusetts ~ Health Care Proxy Christian Version
~ Massachusetts ~ Health Care Proxy Christian Version NOTICE TO PERSON MAKING THIS DOCUMENT You have the right to make decisions about your health care. No health care may be given to you over your objection,
Regulation STUDENTS August 13, Management of Students with Cancer in the School Setting
August 13, 2008 Management of Students with Cancer in the School Setting These are guidelines to follow when the school is informed of the presence of a student with a cancer diagnosis. I. Modern advanced
PATIENT INFORMATION INSURANCE INFORMATION
PATIENT INFORMATION Patient Name: Date of Birth: SSN: Cell Number: Cell Phone Provider: Home Number: Work Number: Home Address: City/State: Zip: Employer: Occupation: E-Mail: Relationship Status: S M W
Percutaneous nephrolithotomy (PCNL)
Percutaneous nephrolithotomy (PCNL) This leaflet explains more about the PCNL procedure to clear kidney stones, including the benefits, risks and any alternatives and what you can expect when you come